]. As candidin and trichophytin have been injected in human beings for decades without undesirable consequences, they very likely could be used as adjuvants associated with allergens without raising untoward reactions.
The facts described above justify the carrying out of research aimed at providing support for the use of candidin and/or trichophytin as adjuvants in immunotherapeutic antiallergy preparations. In the present work, the nature of the cytokines that were produced by allergic patients' and healthy individuals' peripheral blood mononuclear cells (PBMC), when they were incubated in vitro with candidin or trichophytin, was investigated. This was carried out to find out whether these fungal extracts would elicit recall immune responses that could potentially inhibit a type I hypersensitivity reaction without eliciting a potentially pathogenic Th17 immune response. This was indeed observed with the PBMC from most donors.
Materials & methods Blood donors
All blood donors, aged between 21 and 40 years, signed an informed consent to participate in the present research. They were classified into allergic (n = 9) and nonallergic (healthy individuals; n = 7) donors based on the results of skin prick tests using extracts from six common allergens (Alergolatina Produtos Alergênicos Ltd, Rio de Janeiro, Brazil), on the history of allergic symptoms and according to measurement of the levels of specific IgE to Blomia tropicalis, Dermatophagoides pteronyssinus, Periplaneta americana, Blattella germanica and Ascaris lumbricoides using the ImmunoCAP assay (Phadia Diagnostics AB, Uppsala, Sweden). The research was approved by the institutional Ethics Committee for Research in Human Subjects. Health, Rio de Janeiro, Brazil. C. albicans was cultivated in Sabouroud medium in a shaker at 25°C for 48 h (strains A and B) and 72 h (strain CT). The yeast was collected and washed by centrifugation in endotoxin-free 0.15 M phosphate-buffered saline, pH 7.2 (PBS), and stored at -70°C until use. T. rubrum was cultivated in the same conditions for 14 days, collected from the medium and washed with phosphate-buffered saline (PBS). The fungi were lyzed using an electrical triturator in the presence of silica beads (BioSpec Products, Inc, Bartlesville, OK, USA) and of PBS. Following centrifugation at 10,000 g for 20 min at 4°C, the supernatants of the C. albicans lysate (candidin) and of the T. rubrum lysate (trichophytin) were collected, filtered through a polystirene filter with 40-µm-diameter pores, aliquoted and stored at -70°C until used. Protein concentrations were measured using the Folin reagent (Bio-Rad Laboratories, Richmond, CA, USA). Stimulation of PBMC by fungal extracts PBMC were isolated from venous blood by centrifugation on HISTOPAQUE 1077 solution (SigmaAldrich, MO, USA). PBMC (2 × 10 cells/well) were stimulated by fungal extracts containing 5 or 50 µg of protein per ml in 96-well plates (200 µl/well) in RPMI 1640 medium (Gibco, NY, USA) supplemented with 10% fetal bovine serum (Gibco), 1% glutamine, 100 U/ml penicillin, 100 &mu;g/ml streptomycin and 20 &mu;g/ml polymyxin B (Sigma-Aldrich), for 24 h (for quantification of IL-10, TNF-[alpha], IL-6, IL-12 and TGF-[beta]) or for 120 h (for quantification of IL-5, IL-17 and IL-13), at 37°C and 5% CO . Polymixyn B was not used in wells stimulated by lipopolysaccharide (LPS). In negative control cultures, the cells were incubated with supplemented medium alone.
Preparation of candidin & trichophytin

Cell viability assay
After cell culture for 24 h and collection of the supernatant, nine randomly chosen PBMC were subjected to a cytotoxicity assay utilizing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich).
Briefly, one million PBMC were incubated with 600 µg/ml of MTT in 100 µl of RPMI medium in wells of a 96-well microtiter plate for 4 h at 37°C and 5% CO . After this period, the microculture plate was centrifuged for 5 min at 128 × g and 4°C, the supernatants were discarded by inversion, 100 µl of dimethylsulfoxide (Sigma-Aldrich) were added to each well, the microculture plate shaken on a plate shaker for 10 min and the optical densities of the reaction mixtures read with a 490-nm wavelength light. Cell viability values were expressed as the absorbance percentage in relation to those of negative control (not containing fungal extract) cultures.
Cytokine measurements
The concentrations of cytokines were assessed using commercially available ELISA duo-sets (Pharmingen, BD Biosciences, San Diego, CA, USA), according to manufacturer's instructions, and a 3,3, 5,5-tetramethylbenzidinedihydrochloride substrate system (Amresco, LLC, OH, USA). The reactions were stopped by the addition of 50 µl of 2 N sulfuric acid (Sigma-Aldrich) and the absorbances of 450-nm wavelength light were measured. The increases in cytokine concentrations in a stimulated PBMC culture were calculated by subtracting the cytokine levels in the nonstimulated culture from the levels in the stimulated culture. For most cytokines, the levels in unstimulated cultures were relatively low: a 34-179 pg range was observed for IL-10; a 19-382 pg range for TNF-[alpha], with a 663 pg outsider; a 46-243 pg range for IL-5; a 25-83 pg range for IL- were much higher than those of these other cytokines in all cultures, ranging from 2146 to 4236 pg, with an outsider of 8290 pg. As for IFN-[gamma], there was a great variation in the spontaneous production of the cytokine, whose concentrations in culture's supernatants ranged from 8 to 927 pg.
Statistical analysis
The statistical significance of differences in cytokine concentrations between stimulated and nonstimulated cultures were determined by Friedman's test, followed by Dunn's post-test.
Differences of p [less than or equal to] 0.05 were considered significant. Fisher's exact probability test was used to assess the statistical significance of differences in the proportion that fungal antigen-stimulated and unstimulated PBMC presented a given pattern of produced cytokines and in the frequencies of production of IL-17 in candidin-and trichophytinstimulated cultures. Results
Cell viability in fungal extract-stimulated PBMC cultures
The mean percentages of viable cells in PBMC cultures to which 50 µg/ml of candidin and trichophytin extracts were added, in relation to untreated cultures, were 98.2 and 99.0, respectively.
Cytokine production by fungal extract-stimulated PBMC
The fungal extract concentrations (5 and 50 µg/ml) that were utilized in the present work did not differ in terms of the patterns of cytokine level increases that they induced in the different PBMC (Table 1) , whereas trichophytin significantly increased the production of IL-12 by healthy individuals' PBMC, and of TGF-[beta] by allergic patients' PBMC (Table 1) . Although statistically significant increases could be observed for some cytokines in cultures of allergic donors' PBMC and not in cultures of nonallergic donors' PBMC, or vice versa (Table 1) (Figure 1) . In most cultures, however, these increases in regulatory cytokines were accompanied by increases in proinflammatory cytokines (Figures 1 & 2) . Trichophytin increased regulatory cytokines levels exclusively, without augmenting any of the investigated proinflammatory cytokines, in two out of seven nonallergic individuals' PBMC (nonallergic donors 2 and 4; Figures 1 & 2) and in three out of nine allergic patients' PBMC (allergic donors 2, 3 and 4; Figures 1 & 2 ). An exclusive increase in regulatory cytokine levels was not seen in any culture of candidin-stimulated PBMC (Figures 1 & 2) . (Figures 1 & 2) . This differed significantly from what was seen in unstimulated cultures (p = 0.035 and 0.0002, respectively; Fisher's exact probability test). Although a higher proportion of PBMC with these patterns of cytokine production was seen in the allergic patients' group than in the nonallergic group, this difference was not statistically significant (p = 0.26, two-tailed Fisher's exact probability test).
The levels of the allergy-associated Th2 cytokine IL-5 were increased in PBMC cultures from three out of seven healthy individuals (nonallergic donors 3, 5 and 7, Figure 2 ) and in none of the alergic patients' PBMC that were stimulated by candidin. Trichophytin, on the other hand, stimulated the production of IL-5 by just one of the nonallergic donors' PBMC (nonallergic donor 7) and by none of the allergic donors' PBMC. The levels of IL-13, another allergy-associated cytokine, were not increased when candidin was added to cultures of nonallergic donors' PBMC ( Figure 2 ). Only a small increase was seen in one of the allergic patients' PBMC cultures due to the addition of that fungal extract (allergic donor 9; Figure 2 ). As for trichophytin-stimulated PBMC, the level of IL-13 was increased in only one of the cultures of nonallergic individuals' PBMC (nonallergic donor 5; Figure 2 ) and in none of the nine allergic patients' PBMC cultures (Figure 2 ). IL-17 levels were increased in cultures of trichophytin-stimulated PBMC from one out of seven healthy individuals (donor 5; Figure 2) , and from none of the nine alergic patients (donors 6 and 8; Figure 2 ), whereas it was increased in cultures from candidin-stimulated PBMC from four out of seven healthy individuals (nonallergic donors 1, 3, 5 and 7; Figure 2) , and from five out of nine allergic patients (allergic donors 2-5 and 9; Figure 2 ). Combining the data from allergic and nonallergic individuals for trichophytin (1 out of 16 individuals with PBMC producing IL-17) and for candidin (9 out of 16 individuals with PBMC producing IL-17), the difference observed between the frequencies of stimulation of IL-17 production by the two extracts was highly significant (p = 0.0059, two-tailed Fisher's exact probability test).
Discussion
The viability of the PBMC was not affected by incubation with up to 50 µg/ml of candidin or trichophytin for 24 h, as shown by the absence of additional MTT reduction. Cell death, therefore, did not affect the variation in cytokine production caused by the stimulation of the cells by the fungal extracts. The present work, although studying a relatively small sample of individuals, clearly shows that trichophytin and/or candidin elicited the production of regulatory and/or Th1-associated cytokines without stimulating the production of the respiratory allergy-associated Th2 cytokines and IL-17 in a proportion of healthy (four out of seven in the present study) and allergic (nine out of nine in the present study) individuals' PBMC. These allergic patients, therefore, are candidates for receiving antiallergy immunotherapeutic preparations containing the allergen(s) and, as adjuvant, only candidin (allergic donor 8; Figures 1 & 2) ; only trichophytin (allergic donors 2, 3, 4, 5 and 9; Figure   2 ), or both (allergic donors 1, 6 and 7; Figure 2) . These results open, therefore, the possibility of using customized immunotherapeutic preparations that would contain only the adjuvant(s) that did not induce Th2 cytokine or IL-17 production in that particular patient. For obvious reasons, adjuvants that are candidates for inclusion in antiallergy therapeutic vaccines should not induce the production of these cytokines, as they are directly associated with the pathogenesis of respiratory allergy [ ]. A customized immunotherapy that would involve the previous realization of a cellculture procedure and the assessment of cytokine production would be relatively expensive. Its price, however, should be weighed against that of carrying out a less effective immunotherapeutic procedure for years. Candidin significantly stimulated the production of three cytokines by healthy individuals' PBMC (IL- (Table 1) . Candidin, therefore, seems to be more stimulatory than trichophytin for human PBMC. In fact, candidin stimulated the production of IL-17 by the PBMC from a larger number of donors (9 out 16; Figure 2 ) than trichophytin (1 out of 16; p = 0.0059, two-tailed Fischer's exact probability test).
However, PBMC of a larger number of individuals, and in different geographic areas, should be tested in order to determine which of the two preparations, trichophytin or candidin, would be the best antiallergy adjuvant candidate. Although current knowledge highlights the role of T regulatory cell-mediated immune regulation, defined mechanisms that lead to successful clinical outcomes of allergen-specific immunotherapy still remains an open area of research [ ].
An interesting finding, which may be relevant for the possible use of trichophytin and candidin as adjuvants in antiallergy immunotherapy, is that these fungal extracts did not stimulate the production of Th-2 cytokines by allergic donor' PBMC more intensely than by healthy donor' PBMC. Allergic patients, therefore, do not seem to have an immune system biased toward the production of of studies aimed at investigating whether there are proteins in these fungus extracts that preferentially induce the production of regulatory cytokines. These proteins would be ideal Treginducing adjuvant candidates for inclusion in immunotherapeutic vaccines for inflammatory diseases, such as allergy and autoimmune diseases. An interesting possibility, therefore, would be the purification of molecules from candidin or trichophytin that would specifically stimulate an immune regulatory response that, in its turn, would control the allergic immune response, or alternatively, identify those molecules and have they produced by the recombinant DNA technology.
Future perspective
New tolerogenic antiallergy immunotherapies should be available in the next 5-10 years. These immunotherapies will probably utilize preparations containing Treg-inducing adjuvants. It is possible that molecules obtained from candidin or trichophytin might be used as tolerogenic adjuvants. Table 1 . Statistical significance of variations in cytokine production by fungal extract-stimulated peripheral blood mononuclear cells.
Produced cytokine Peripheral blood mononuclear cells from Comparison
As assessed by Friedman's nonparametric test followed by Dunn's post-test. * PBMC were cultivated in vitro in the presence or absence of these extracts at 37°C and 5% CO during 24 and 120 h.
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